Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KPTI
SELLKaryopharm Therapeutics Inc. · Healthcare · United States · $168M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to developing and commercializing novel cancer therapies, primarily focusing on its proprietary nuclear export inhibitors, with XPOVIO as its lead approved product. The company's competitive moat lies in its unique drug class and intellectual property in nuclear export modulation, addressing significant unmet needs in oncology. Karyopharm operates as an innovative biotech, expanding the indications for its approved drug and advancing its pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.1M | 146.0M | 145.2M | 146.1M | -2.4% | 151.1M | 138.2M | 149.0M | 1.0% |
| EPS | -10.09 | -6.35 | -3.51 | -17.93 | — | -12.91 | — | — | — |
| Shares | 22.7M | 22.7M | 22.7M | 18.3M | -19.2% | 22.7M | — | — | — |
| Debt | 179.1M | 177.0M | 194.5M | 233.6M | 9.3% | 303.2M | — | — | — |
| Equity | -16.7M | -136.2M | -186.0M | -292.9M | — | — | — | — | — |
| Op CF | -149.6M | -92.7M | -127.5M | -75.4M | — | -59.1M | — | — | — |
| Inv CF | -104.3M | 7.9M | 95.5M | 43.4M | — | — | — | — | — |
| Fin CF | 193.7M | 1.1M | 41.6M | 30.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KPTI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc.(you) | $168M | 24 | SELL |
| ACOG | Alpha Cognition Inc. Common Stock | $172M | 26 | SELL |
| EQ | Equillium, Inc. | $157M | 23 | SELL |
| NRXP | NRx Pharmaceuticals, Inc. | $161M | 27 | SELL |
| NKTX | Nkarta, Inc. | $162M | 29 | SELL |
| MGNX | MacroGenics, Inc. | $235M | 25 | SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $224M | 21 | SELL |
| HURA | TuHURA Biosciences, Inc. | $134M | 20 | SELL |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $170M | 15 | STRONG SELL |
| WHWK | Whitehawk Therapeutics, Inc. | $183M | 31 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%